SCHEMBL17995339

SCHEMBL17995339

c1ccc(-c2nc(-c3ccccc3)nc(-c3nc(-c4ccccc4)nc(-c4cc5ccccc5c5ccccc45)n3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.51
L3MBTL1 Q9Y468 3/20 0.45
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
RECQL P46063 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 5/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
HPGD P15428 4/20 0.43
KDM4E B2RXH2 3/20 0.43
MPI P34949 1/20 0.43
TSHR P16473 3/20 0.42
ADORA2A P29274 3/20 0.42
ADORA1 P30542 3/20 0.42
ADORA3 P0DMS8 2/20 0.42
ADORA2B P29275 2/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18327468 0.98 CYP11B1 (0.53) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL19271420 0.98 CYP11B1 (0.53) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL17995347 0.96 CYP11B1 (0.49) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL18327507 0.94 CYP11B1 (0.50) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL21394109 0.94 CYP11B1 (0.50) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL21394564 0.94 CYP11B1 (0.50) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL17932612 0.94 CYP11B1 (0.50) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL17932621 0.91 CYP11B1 (0.47) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL17932656 0.91 CYP11B1 (0.47) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1
SCHEMBL17932616 0.91 CYP11B1 (0.47) CYP11B1L3MBTL1MAPTSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10418562-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2019-09-17 US disclosed
US-20160233429-A1 Organic Electroluminescent Materials and Devices UNIVERSAL DISPLAY CORPORATION 2016-08-11 US disclosed
US-20160233429-A1 Organic Electroluminescent Materials and Devices UNIVERSAL DISPLAY CORPORATION 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10418562-B2 Organic electroluminescent materials and devices NBAS, TBCB, SLC1A2 CYP11B1 2289/4885L3MBTL1 640/4885MAPT 304/4885
US-20160233429-A1 Organic Electroluminescent Materials and Devices NBAS, TBCB, SLC1A2 CYP11B1 2289/4885L3MBTL1 640/4885MAPT 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.